Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritis
Stefano Gentileschi
BackgroundThere is currently scarce data on the real-world effectiveness and safety of upadacitinib in patients with axial spondyloarthritis (axSpA). This study evaluated clinical outcomes and drug retention rate (DRR) at 6, 12, and 24 months in patients initiating upadacitinib for axSpA.MethodsThis prospective, observational study enrolled consecutive patients with radiographic axSpA (r-axSpA) or non-radiographic axSpA (nr-axSpA) initiating upadacitinib between December 2022 and January 2025 at